Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMT Aimmune Therapeutics	$34.49	$34.46	$10.09 ▼ $37.00	$2.26B	1.76	1.71 million shs	N/A
BPMC Blueprint Medicines	$128.23 0.0%	$101.93	$73.04 ▼ $128.34	$8.26B	0.84	1.23 million shs	3.35 million shs
CORT Corcept Therapeutics	$71.85 +1.3%	$71.47	$28.09 ▼ $117.33	$7.43B	0.19	1.14 million shs	789,626 shs
ROIV Roivant Sciences	$11.11 +0.3%	$10.87	$8.73 ▼ $13.06	$7.70B	1.16	5.61 million shs	6.17 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMT Aimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
BPMC Blueprint Medicines	+0.23%	+0.22%	+26.12%	+43.15%	+21.51%
CORT Corcept Therapeutics	+1.20%	+0.47%	-5.57%	+25.49%	+144.74%
ROIV Roivant Sciences	-2.12%	0.00%	+2.69%	+3.45%	+3.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	1.1907 of 5 stars	2.1	2.0	0.0	0.0	2.9	0.8	0.6
CORT Corcept Therapeutics	4.6593 of 5 stars	3.5	1.0	0.0	4.2	3.3	4.2	1.9
ROIV Roivant Sciences	2.2438 of 5 stars	3.5	3.0	0.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMT Aimmune Therapeutics	0.00	N/A	N/A	N/A
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.13% Downside
CORT Corcept Therapeutics	3.00	Buy	$138.25	92.41% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	57.52% Upside

Current Analyst Ratings Breakdown

Latest AIMT, BPMC, ROIV, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	$1.66 per share	N/A
BPMC Blueprint Medicines	$508.82M	16.28	N/A	N/A	$4.70 per share	27.28
CORT Corcept Therapeutics	$675.04M	11.29	$1.27 per share	56.41	$6.49 per share	11.07
ROIV Roivant Sciences	$29.05M	259.99	N/A	N/A	$7.45 per share	1.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMT Aimmune Therapeutics	-$248.50M	-$3.97	N/A	N/A	N/A	N/A	-164.99%	-89.50%	N/A
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.28	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
CORT Corcept Therapeutics	$141.21M	$1.16	61.94	38.84	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest AIMT, BPMC, ROIV, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMT Aimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMT Aimmune Therapeutics	0.73	7.53	7.40
BPMC Blueprint Medicines	1.01	2.80	2.75
CORT Corcept Therapeutics	N/A	3.07	2.96
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMT Aimmune Therapeutics	74.47%
BPMC Blueprint Medicines	N/A
CORT Corcept Therapeutics	93.61%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
AIMT Aimmune Therapeutics	13.75%
BPMC Blueprint Medicines	4.21%
CORT Corcept Therapeutics	20.50%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMT Aimmune Therapeutics	228	65.45 million	N/A	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
CORT Corcept Therapeutics	300	106.04 million	84.31 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

AIMT, BPMC, ROIV, and CORT Headlines

Recent News About These Companies

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16 at 7:00 AM | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Vivek Ramaswamy Sells 547,430 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

June 8, 2025 | americanbankingnews.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | insidertrades.com

California State Teachers Retirement System Acquires 37,982 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

May 30, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript

May 30, 2025 | insidermonkey.com

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings

May 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMT, BPMC, ROIV, and CORT Company Descriptions

Aimmune Therapeutics NASDAQ:AIMT

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Blueprint Medicines NASDAQ:BPMC

$128.23 -0.02 (-0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$128.22 -0.01 (-0.01%)

As of 04:08 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corcept Therapeutics NASDAQ:CORT

$71.85 +0.95 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$72.09 +0.24 (+0.33%)

As of 07:11 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Roivant Sciences NASDAQ:ROIV

$11.11 +0.03 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$11.10 0.00 (-0.05%)

As of 05:39 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time